• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖对上皮性卵巢癌手术并发症及术后预后的影响:一项荟萃分析。

The effects of obesity on surgical complications and postoperative prognosis of epithelial ovarian cancer: a meta-analysis.

作者信息

Sheng Jingjing, Li Chu, Zhang Jiali, Jin Zujian, Zhou Yun Xiao, Huang Yiping

机构信息

Department of Gynecology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.

Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

BMC Surg. 2025 Mar 27;25(1):119. doi: 10.1186/s12893-025-02770-7.

DOI:10.1186/s12893-025-02770-7
PMID:40148940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11948763/
Abstract

OBJECTIVE

To comprehensively evaluate and compare surgical outcomes of obese patients versus non-obese patients for surgical complications and postoperative prognosis due to epithelial ovarian cancer (EOC).

METHODS

Studies were obtained from database search systems of Medline (PubMed) and Embase. Data were analyzed by the meta-analysis method and the random-effect or fixed-effect model. The heterogeneity between the studies was evaluated by I2 index and the data were analyzed using STATA version 15.1 and Review Manager version 5.4.

RESULTS

14 studies with 4858 cases of proven epithelial ovarian cancer who underwent extensive surgery were included. Obesity may be a risk factor of the low surgical complex score (RR1.08, 95% CI 1.01-1.15, p = 0.05), but had no manifesting difference in the surgical complications score compared non-obesity group (RR 0.50, 95% CI 0.07-3.79, p = 0.501 and RR 0.60, 95% CI 0.22-1.63, p = 0.316). Obesity EOC patients who undergone surgery tended to be correlated with surgical complications, such as wound infection (RR 2.71, 95% CI 1.59-4.61, p = 0.000), intestinal complications (RR 2.09, 95% CI 1.00-4.35, p = 0.000), and 30-readmission rate (RR 1.84, 95% CI 1.16-2.93, p = 0.000). Obese patients were more likely to have shorter prognosis free survival (PFS) (SMD 0.62-year, 95% CI-0.13 to 0.15), but the results did not discover a significant difference in overall survival (OS)between obesity and non-obesity. (SMD 0.01-year, 95% CI-0.13 to 0.15) CONCLUSIONS: Obesity affects the difficulty of ovarian cancer surgery, and a negative relationship between obesity and surgical complications is observed. Obesity is a potential risk factor for prognosis of EOC patients. Attention is played on determining what kind of case should be benefit most from this surgery to minimize the rates of operative complications and postoperative mortality.

PROSPERO REGISTRATION NUMBER

CRD 42,023,434,781.

摘要

目的

全面评估和比较肥胖患者与非肥胖患者因上皮性卵巢癌(EOC)进行手术的并发症及术后预后情况。

方法

从Medline(PubMed)和Embase的数据库检索系统中获取研究。采用荟萃分析方法及随机效应或固定效应模型对数据进行分析。通过I²指数评估研究间的异质性,并使用STATA 15.1版和Review Manager 5.4版对数据进行分析。

结果

纳入了14项研究,共4858例经证实患有上皮性卵巢癌并接受广泛手术的病例。肥胖可能是手术复杂程度评分较低的一个危险因素(风险比率[RR]1.08,95%置信区间[CI]1.01 - 1.15,p = 0.05),但与非肥胖组相比,手术并发症评分无明显差异(RR 0.50,95% CI 0.07 - 3.79,p = 0.501;RR 0.60,95% CI 0.22 - 1.63,p = 0.316)。接受手术的肥胖EOC患者往往与手术并发症相关,如伤口感染(RR 2.71,95% CI 1.59 - 4.61,p = 0.000)、肠道并发症(RR 2.09,95% CI 1.00 - 4.35,p = 0.000)以及30天再入院率(RR 1.84,95% CI 1.16 - 2.93, p = 0.000)。肥胖患者的无进展生存期(PFS)更可能较短(标准化均数差[SMD]为0.62年,95% CI -0.13至0.15),但结果未发现肥胖与非肥胖患者在总生存期(OS)上有显著差异(SMD为0.01年,95% CI -0.13至0.15)。结论:肥胖会影响卵巢癌手术的难度,且观察到肥胖与手术并发症之间存在负相关关系。肥胖是EOC患者预后的一个潜在危险因素。应关注确定哪种病例能从该手术中获益最大,以尽量降低手术并发症发生率和术后死亡率。

国际前瞻性系统评价注册编号

CRD 42,023,434,781

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/f59f772ff77e/12893_2025_2770_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/e079b85fd443/12893_2025_2770_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/3f59f7629a00/12893_2025_2770_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/712ec278aab7/12893_2025_2770_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/88b5531fef82/12893_2025_2770_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/27f11c432ab2/12893_2025_2770_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/f59f772ff77e/12893_2025_2770_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/e079b85fd443/12893_2025_2770_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/3f59f7629a00/12893_2025_2770_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/712ec278aab7/12893_2025_2770_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/88b5531fef82/12893_2025_2770_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/27f11c432ab2/12893_2025_2770_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0080/11948763/f59f772ff77e/12893_2025_2770_Fig6_HTML.jpg

相似文献

1
The effects of obesity on surgical complications and postoperative prognosis of epithelial ovarian cancer: a meta-analysis.肥胖对上皮性卵巢癌手术并发症及术后预后的影响:一项荟萃分析。
BMC Surg. 2025 Mar 27;25(1):119. doi: 10.1186/s12893-025-02770-7.
2
Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.卵巢癌患者术后静脉血栓栓塞症的发生率及危险因素:系统评价和荟萃分析。
Gynecol Oncol. 2021 Feb;160(2):610-618. doi: 10.1016/j.ygyno.2020.11.010. Epub 2020 Nov 19.
3
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.晚期上皮性卵巢癌初始治疗中,术前新辅助化疗与手术加化疗的比较。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub7.
4
Oncological outcomes of fertility-sparing surgery versus radical surgery in stage - epithelial ovarian cancer: a systematic review and meta-analysis.保留生育功能的手术与根治性手术治疗Ⅰ期上皮性卵巢癌的肿瘤学结局:系统评价和荟萃分析。
World J Surg Oncol. 2024 Jun 25;22(1):170. doi: 10.1186/s12957-024-03440-3.
5
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.新辅助化疗在手术前与手术后化疗用于晚期卵巢上皮癌的初始治疗。
Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6.
6
Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.微创外科与开腹手术治疗上皮性卵巢癌的疗效和安全性:系统评价和荟萃分析。
Gynecol Oncol. 2024 Nov;190:42-52. doi: 10.1016/j.ygyno.2024.08.011. Epub 2024 Aug 16.
7
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较
Cochrane Database Syst Rev. 2021 Feb 5;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub5.
8
Impact of obesity on surgical and oncologic outcomes in ovarian cancer.肥胖对卵巢癌手术和肿瘤学结果的影响。
Gynecol Oncol. 2014 Oct;135(1):19-24. doi: 10.1016/j.ygyno.2014.07.103. Epub 2014 Aug 7.
9
Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.新辅助化疗与初次肿瘤细胞减灭术治疗卵巢癌患者的疗效和安全性:一项荟萃分析。
J Gynecol Oncol. 2020 Mar;31(2):e12. doi: 10.3802/jgo.2020.31.e12. Epub 2019 Oct 21.
10
Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.晚期(II-IV期)上皮性卵巢癌女性术后使用干扰素的情况。
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD009620. doi: 10.1002/14651858.CD009620.pub2.

本文引用的文献

1
The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer.选定的脂肪细胞因子在卵巢癌和子宫内膜癌中的作用。
Cells. 2023 Apr 9;12(8):1118. doi: 10.3390/cells12081118.
2
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Factors Predicting 30-Day Grade IIIa-V Clavien-Dindo Classification Complications and Delayed Chemotherapy Initiation after Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Prospective Cohort Study.晚期卵巢癌减瘤手术后30天内Clavien-Dindo分类IIIa-V级并发症及延迟化疗起始的预测因素:一项前瞻性队列研究
Cancers (Basel). 2022 Aug 29;14(17):4181. doi: 10.3390/cancers14174181.
4
Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses.与卵巢癌相关因素的调查:系统评价和荟萃分析的伞状综述。
J Ovarian Res. 2021 Nov 11;14(1):153. doi: 10.1186/s13048-021-00911-z.
5
ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN-trial).ECOG 和 BMI 作为卵巢癌患者术后严重并发症的术前危险因素:一项前瞻性研究(RISC-GYN 试验)的结果。
Arch Gynecol Obstet. 2021 Nov;304(5):1323-1333. doi: 10.1007/s00404-021-06116-5. Epub 2021 Jun 24.
6
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.CT 扫描评估的内脏肥胖和肌肉量与晚期卵巢癌患者的手术结局相关:一项回顾性队列研究。
Gynecol Oncol. 2021 Jan;160(1):187-192. doi: 10.1016/j.ygyno.2020.10.015. Epub 2020 Oct 21.
7
Treatment of epithelial ovarian cancer.上皮性卵巢癌的治疗。
BMJ. 2020 Nov 9;371:m3773. doi: 10.1136/bmj.m3773.
8
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.新辅助化疗不会不成比例地影响肥胖的晚期卵巢癌患者的术后并发症发生率或化疗时间。
Gynecol Oncol. 2020 Dec;159(3):687-691. doi: 10.1016/j.ygyno.2020.09.011. Epub 2020 Sep 18.
9
The Influence of the Preoperative Status on the Risk of Postoperative Complications After Cytoreductive Surgery for Advanced-stage Ovarian Cancer.术前状态对晚期卵巢癌细胞减灭术后术后并发症风险的影响。
In Vivo. 2020 Mar-Apr;34(2):839-844. doi: 10.21873/invivo.11846.
10
The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.在减瘤手术和热灌注化疗后,体重指数极端情况对无病生存期和总生存期的影响。
J Gastrointest Oncol. 2019 Apr;10(2):194-202. doi: 10.21037/jgo.2018.12.05.